| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Rilpivirine (IM) RPT | Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Decreased rilpivirine effects |
Use alternative agents |
|||
| Lenacapavir Rifapentine | Red: Avoid combination | Do not coadminister: reduced levels of lenacapavir | Potential loss of antiviral efficacy |
Use alternative agents |
|||
| Darunavir RPT 923 | Red: Avoid combination | Do not coadminister: Potential for decreased darunavir levels | Potential loss of antiviral efficacy |
Use alternative agents |
|||
| Tenofovir alafenamide RPT 723 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of TAF | Potential decrease in antiretroviral efficacy |
Not studied |
Not studied |
Contraindicated. Use alternative agents. |
|
| Rilpivirine RPT 661 | Red: Avoid combination | Do not coadminister: Reduced levels of rilpivirine | |||||
| Nevirapine RPT 621 | Red: Avoid combination | Do not coadminister: Reduced levels of nevirapine | Decreased nevirapine effects |
Cmin decreased 27% |
Contraindicated. Use alternative agents. |
||
| Etravirine RPT 544 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of etraviorine | Potential decreased etravirine effects |
||||
| Efavirenz RPT 431 | Green: Administer standard doses | Administer standard doses | Efavirenz AUC decreased 14%; Cmin decreased 15% |
900 mg Q week | |||
| Cabotegravir RPT 340 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of CAB | Potential decrease in antiretroviral efficacy |
Not studied |
Not studied |
Contraindicated. Use alternative agents. |
|
| Raltegravir RPT 286 | Green: Administer standard doses | Adjust dosing to avoid reduced levels of raltegravir | Potential for increased raltegravir adverse effects if given with rifapentine once weekly; potential for loss of antiviral response if rifapentine coadministered daily |
When given with rifapentine once weekly for 3 weeks raltegravir AUC increased 79%, Cmax increased 89% and Cmin decreased 12%. When given with rifapentine for 10 daily doses, Cmin decreased 41% |
900 mg once weekly for 3 weeks or 600 mg once daily for 10 scheduled doses (days 1, 4?8 and 11?14) | When coadministering with once weekly rifapentine use raltegravir 400 mg BID. Do not coadminister raltegravir with once daily rifapentine. |
|
| Raltegravir RPT 284 | Yellow: Adjust dosing | Adjust dosing to avoid reduced levels of raltegravir | Raltegravir AUC increased 73%; Cmax increased 89%; Cmin decreased 44% |
900 mg PO once weekly | When coadministering with once weekly rifapentine use raltegravir 400 mg BID. Do not coadminister raltegravir with once daily rifapentine. |
||
| Elvitegravir RPT 220 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of elvitegravir | Potential decrease in antiretroviral efficacy |
Use alternative agents |
|||
| Dolutegravir RPT 119 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of dolutegravir | Potential decrease in antiretroviral efficacy |
Not studied (may decreased dolutegravir levels) |
Not studied |
Contraindicated. Use alternative agents. |
|
| Bictegravir RPT 74 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of BIC | Potential decrease in antiretroviral efficacy |
Not studied |
Not studied |
Use alternative agents |
|
| Maraviroc RPT 58 | Green: Administer standard doses | Do not coadminister: Potential for reduced levels of maraviroc | Potential decrease in antiretroviral efficacy |
Use alternative agents |
|||
| Fostemsavir RPT 23 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of temsavir | Potential decrease in antiretroviral efficacy |
Contraindicated. Use alternative agents. |
